À être construit d’ici 2022 alors rien qui devrait changer au court terme mais les compagnies impliquées sont intéressantes (Genmab et Merus) : ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe’s Most Competitive Science Region
The Accelerator: New Life Sciences building at Utrecht Science Park
Les initiés achètent depuis quelques jours:
Filing
Date
Transaction
Date
Insider Name
Ownership
Jan 20/20
Jan 17/20
Bath, Jennifer Lynne
Direct Ownership
Common Shares
10 - Acquisition in the public market
9,000
$0.630
Jan 16/20
Jan 16/20
Lundstrom, Brian
Direct Ownership
Common Shares
10 - Acquisition in the public market
69,000
$0.440
USD
Jan 10/20
Jan 9/20
Burke, Robert
Control or Direction
Common Shares
10 - Acquisition in the public market
28,000
$0.550
Jan 10/20
Jan 9/20
Burke, Robert
Direct Ownership
Common Shares
10 - Acquisition in the public market
25,000
$0.550
IPA might be a Coronavirus play
Article de il y a 2 ans…
C’est quand même drôle de voir les projections financières à des années lumières de ce qui se produira!
32M$ pour FY20 (terminant le 31 Avril 2020).
(long et éternel chialeur)
ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program
ca sent le coup de pompe avant d’essayer de lever des fonds./
Immunoprecise to focus on developing COVID-19 vaccine
2020-02-20 14:47 ET - News Release
Dr. Jennifer Bath reports
IMMUNOPRECISE LAUNCHES CORONAVIRUS VACCINE AND THERAPEUTIC ANTIBODY PROGRAM
Immunoprecise Antibodies Ltd. is committed to the development of innovative vaccines against the new coronavirus originating in Wuhan, China (SARS-CoV-2), as well as coronavirus-neutralizing antibodies, addressing both prophylactic and therapeutic measures to fight the virus and its associated disease, COVID-19.
IPA’s Rapid Research and Development (RR&D) Team is leveraging its unique ability to address global, pandemic crises in an abbreviated timeframe. To date, the virus has caused approximately 1,875 deaths and over 74,000 known infections and is rapidly expanding worldwide. ImmunoPrecise has designated Dr. Ilse Roodink, the chairwoman of IPA’s subsidiary Talem Therapeutic’s scientific committee, as the Coronavirus Global Project Leader. Under her supervision, the Company has embarked on a global response and properly designed campaign. The sophisticated infrastructure of IPA significantly contributed to a quick, but sensible, response initiated by the design and production of relevant SARS-CoV-2 target antigens to facilitate the upcoming identification of prophylactic and therapeutic compounds using IPA’s proprietary discovery platforms (including B Cell Select and DeepDisplay) and Talem’s access to the leading transgenic animal platform OmniAbtrademark for direct generation of human antibodies.
“We believe that ImmunoPrecise will make an impressive contribution to the global fight against SARS-CoV-2,” stated Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies. “With the aid of iterative advancements rapidly compiling from across the globe, including data such as the February 19 th release of the prefusion form of the new coronavirus spike glycoprotein, research teams are advancing the collective effort toward the development of efficacious vaccines, therapeutic antibodies, and diagnostics. We grow more determined each day about contributing to this endeavor, as we monitor the rapid, global spread of SARS-CoV-2.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select progressive single-cell interrogation technology and the DeepDisplay custom, OmniAbtrademark-based phage libraries, as well as the Abthena bispecific program. IPA is focused on the next generation of antibody discovery, to deliver the most therapeutically relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise’s discovery and development are conducted in Utrecht and Oss, the Netherlands (U-Protein Express and IPA Europe, respectively), and in Victoria, British Columbia (IPA Canada). The Company operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.
There is no assurance that the Company will be successful in the development of a vaccine and/or therapeutic against the new coronavirus. In particular, the development of a vaccine and/or therapeutic requires significant capital, which will require additional financing by the Company, successful clinical trials and extensive regulatory approvals.
We seek Safe Harbor.
C’était évident qu’un financement s’en venait en regardant le balance sheet et avec la debenture qui arrive à expiration. Ils ont publié une notice hier qui laisse présager que ça s’en vient :
APPENDIX A - NOTICE DECLARING INTENTION TO BE QUALIFIED UNDER NATIONAL
INSTRUMENT 44-101 SHORT FORM PROSPECTUS DISTRIBUTIONS
(“NI 44-101”)
February 19, 2020
TO: BRITISH COLUMBIA SECURITIES COMMISSION
AND TO: ALBERTA SECURITIES COMMISSION
IMMUNOPRECISE ANTIBODIES LTD. (the “Issuer”) intends to be qualified to file a short form
prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable
qualification criteria prior to filing a preliminary short form prospectus. This notice does not
evidence the Issuer’s intent to file a short form prospectus, to enter into any particular financing
or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect
until withdrawn by the Issuer.
IMMUNOPRECISE ANTIBODIES LTD.
“Jennifer Bath”
Jennifer Bath
Chief Executive Officer
Le timing avec la nouvelle du Coronavirus, je suis d’accord que ça a l’air promotionnel.
Maintenant, voyons voir ce qu’ils vont proposer comme financement et surtout, qui va y participer. Ce serait intéressant de voir des institutions ou un joueur stratégique embarquer et venir donner de la crédibilité au potentiel de IPA. Il aurait pu sauter dans le bandwagon du coronavirus dès le début mais apparemment qu’ils travaillent là-dessus depuis 3 semaines et ont attendu de récolter assez de données positives pour être en mesure de les présenter à des joueurs clés.
Si ils sont déjà en discussions avec différents joueurs, ce communiqué peut possiblement mettre de la pression pour arriver à une entente. Pure spéculation ici, on en saura sans doute plus dans les prochains jours/semaines.
BY KAREN TKACH TUZMAN, ASSOCIATE EDITOR | FEB 21, 2020 | 10:52 PM EST
The COVID-19 crisis is mobilizing researchers to crank out therapeutic mAbs from a wide array of patient- and animal-based platforms, with the virus’ spike protein emerging as the consensus target antigen. But the hold-up for access to COVID-19 patient samples means some players’ most promising programs are waiting in the wings.
The speedy publication by Chinese scientists of the genomic sequence of SARS-CoV-2, the virus behind COVID-19, made it possible for companies to get a running start developing vaccines and therapeutics against the disease (see “The Race is On”).
For mAb developers, the sequence made it possible to simulate the new pathogen via recombinant proteins or pseudo-viruses, which are serving as immunization and screening tools until samples of SARS-CoV-2 from patients become more widely available.
Materials and information on the related virus SARS-CoV, which causes severe acute respiratory syndrome (SARS), is also jumpstarting mAb programs. However, a structural paper published in Science on Wednesday sheds light on the limits of extrapolating between SARS-CoV and SARS-CoV-2 (see “Insights on COVID-19 Vax, mAb Development from Spike Structure”).
At least five company and academic teams have disclosed use of specific mAb discovery platforms to take on COVID-19. Collectively, the platforms span at least four species (see Figure: “mAbs on the march against COVID-19”).
Vir Biotechnology Inc. (NASDAQ:VIR) and AbCellera Biologics Inc. are looking for mAbs in recovered patients. However, due to the current lack of access to SARS-CoV-2 samples, both are starting with mAbs from recovered SARS patients that cross-react with SARS-CoV-2.
Vir is deploying the technology it gained through its 2017 acquisition of Humabs Biomed S.A., while AbCellera is tapping its Pandemic Prevention Platform under contract with the Defense Advanced Research Projects Agency (DARPA), in collaboration with the Vaccine Research Center at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) (see “COVID-19 Update”).
Vir has identified two mAbs that bind a region of the SARS-CoV-2 spike protein that the virus uses to infect cells, and is using a pseudovirus expressing the SARS-CoV-2 spike protein to assess whether these and other mAbs can neutralize viral entry.
AbCellera is using a microfluidics-based platform to screen antibodies from individual B cells. The company plans to release an update on its SARS-CoV-2 discovery work in mid-March.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is generating candidate mAbs by immunizing its transgenic VelocImmune mice, which produce human antibody repertoires, with a pseudovirus expressing the SARS-CoV-2 spike protein. The company is also investigating whether candidates it previously generated against MERS could cross-react with SARS-CoV-2.
The New York-based mAb company expanded its preexisting collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to include therapies to treat COVID-19.
A Belgian team led by Flanders Institute for Biotechnology (VIB) and Ghent University professor Xavier Saelens has generated a single domain heavy chain antibody (VHH) candidate by immunizing llamas with a stabilized prefusion conformation of a spike protein domain that’s conserved between SARS-CoV and SARS-CoV-2.
Tim Van Acker, who is BD manager at VIB Innovation & Business, told BioCentury the team’s lead VHH candidate had an IC50 of 0.14 μg/ml in neutralization assays with SARS-CoV, and similar tests with SARS-CoV-2 are ongoing. The group is in the process of humanizing the lead construct and incorporating it into alternative formats such as fusion proteins. It also plans to immunize its llamas with SARS-CoV-2.
“The published sequence made it possible to simulate the new pathogen via recombinant proteins or pseudo-viruses”
Tool companies and CDMOs are jumping into the race.
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced interest from undisclosed companies in using its OmniChicken platform – one of the five transgenic animal technologies in its OmniMab portfolio – to develop mAbs against SARS-CoV-2. The company declined to disclose details on specific programs and their targets.
Other service companies have reported they are developing mAbs against the virus but have not disclosed a specific platform technology or target.
One of Ligand’s partners, antibody discovery service company ImmunoPrecise Antibodies Ltd. (TSX-V:IPA; Pink:IPATF), said Thursday it will combine its B Cell Select and DeepDisplay mAb discovery technologies with the OmniMab platform.
ImmunoPrecise CEO Jennifer Bath declined to disclose whether the company would use Ligand’s chicken, mouse or rat technologies, but said the company will target both viral antigens and the human receptor that mediates SARS-CoV-2 entry, ACE2.
WuXi Biologics Inc. (HKEX:2269) said on Jan. 28 it had “stepped up its efforts in enabling the development of multiple neutralizing antibodies” against SARS-CoV-2 via its “integrated technology platforms.” The CDMO, which did not return requests for comment, said its first batch of mAbs targeting the virus would be ready for preclinical tox testing and first-in-human studies within two months.
ACE2 - Angiotensin-converting enzyme 2
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus. The COVID-19 content is free to all who visit the site.
Coronavirus stock hype proves infectious
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Every public health emergency presents an opportunity for bioharma to justify its existence by springing into action to develop vaccines, diagnostics and treatments; at the same time, some will use mention of the disease as a way to drive up share prices and tap investors for money.
In this regard the current outbreak of coronavirus Covid-19 has stuck to the script, with several vaccines and an antiviral poised to enter the clinic. But for every bona fide effort there are numerous hangers-on, and a rough calculation by Vantage reveals that the outbreak has helped several small and midcap biotechs put on a combined $3.5bn in market valuation.
In the case of several huge gainers there has in fact been very little to show beyond hype in a press release. Some of the small caps jumping on the coronavirus bandwagon include Faron, AIM Immunotech, Novavax, Cerus, Immunoprecise Antibodies and Tonix.
Vantage has analysed the stock market movements between January 20 and February 25 of biopharma companies that have made public announcements on coronavirus. Though the first Covid-19 case was reported last December it was only in the week of January 20 that it became apparent that a global health emergency was in the offing.
Perhaps the most prominent work to develop a treatment involves Gilead, which rose 7% yesterday after starting phase III Covid-19 trials with the nucleotide analogue remdesvir. Though with an IV route this drug is far from optimal, in the view of Baird’s Brian Skorney Gilead is “by far the most plausible [coronavirus stock] to achieve anything besides an overpriced follow-on offering”.
A selection of biopharma’s biggest coronavirus-related stock risers
Company Share price chg Market cap chg ($m) Claim relating to Covid-19
Novacyt 799% 97 Launched coronavirus test
Co-Diagnostics 296% 75 Launched coronavirus test
Cocrystal Pharma 256% 55 Licensed antivirals from Kansas State Uni
Nanoviricides 135% 46 Claims work on a treatment
Zhejiang Hisun Pharmaceutical 52% 769 Approval to put favipiravir into clinical trial
Faron Pharmaceuticals 49% 72 Loose connection to avoiding steroid use
AIM Immunotech 44% 3 Filed patent applications covering Ampligen
Novavax 39% 71 Claims work on vaccine
Q Biomed 34% 17 Partner Mannin claims work on a treatment
Vir Biotechnology 33% 587 Signed deal with Wuxi to develop MAbs
Ibio 32% 10 Deal with CC-Pharming to develop vaccine
Cytosorbents 24% 36 Claims work to launch CytoSorb as treatment
Cerus 20% 224 Loose connection in scientific paper
Moderna 15% 1,125 CEPI funding to develop mRNA vaccine
Regeneron Pharmaceuticals 15% 6,188 HHS agreement on MAb treatments
Inovio Pharmaceuticals 14% 50 Approval to put RNA treatment into clinical trial
Innovation Pharmaceuticals 13% 3 Explores brilacidin as a treatment
Gilead Sciences 11% 9,008 Putting remdesivir into clinical trial
Immunoprecise Antibodies 7% 2 Commits to develop vaccines
CSL 7% 7,224 Partners with Queensland Uni on vaccine
Seegene 6% 38 Launched coronavirus test
Cytodyn 5% 58 To co-develop leronlimab with Longen
Pharmamar 2% 23 Claims work on a diagnostic
Roche 1% 4,800 Assay approved for research use
*Share price movements between 20 Jan and 25 Feb; list not exhaustive. Source: Vantage & stock market announcements.
That financial bets are even being made on the back of a health crisis – a retail investor website recently ran an article entitled “my initial coronoavirus trading plan” – seems distasteful. Still, without hard cash little real work would likely get done to treat such an emergency.
But among the biggest examples of hype stands Novavax, a biotech that has burned through $1.5bn of investor cash with no marketed product to show for it, instead using press releases about the likes of Sars, RSV and bird flu as a prelude to cash calls. Yesterday it announced plans to develop a Covid-19 vaccine.
Faron surged on the mere mention that its failed lead, traumakine, was an interferon-beta, a biological that is a first line of defence against viral infection. Tonix yesterday trumpeted a vaccine collaboration, and while its stock surged 123% it was down over the relevant period owing to a separate trial failure.
Many stock cap movements are exaggerated by the fact they concern micro-cap companies, but taken together the increases in valuation are considerable.
Diagnostics
Predictably, diagnostics groups have recorded some of the largest share price gains, with Novacyt and Co-Diagnostics both dragging themselves out of penny stock territory.
Novacyt on February 17 launched the world’s first CE-marked test for the Covid-19 virus, while Co-Diagnostics followed with its own CE-marked diagnostic a week later, and today followed up with a fund raising. Earlier Pharmamar announced that it was developing a coronavirus test.
In actuality all three were pipped by Roche, which at its full-year results meeting on January 30 said it had already introduced a commercial, if not yet approved, coronavirus assay.
Elsewhere, investors have been piling into Moderna, though some analysts remain sceptical over whether its mRNA approach can resist the virus’s mutation. And Vir Biotechnology, which claims to be working on anti-Covid-19 MAbs, has been dismissed by Baird as being “nowhere close to an effective therapeutic”.
In reality, real progress against this virus is much more likely to be made by big companies or academics centres with established infectious disease expertise. In the corporate worlds this includes: Merck & Co, notable for developing the only Ebola vaccine to get to market; Johnson & Johnson, which owns the vaccine business Crucell; and pharma giants Sanofi and Glaxosmithkline.
Companies of this size are no use to traders hoping to ride a speculative surge. But those chasing the corona trade should remember that these small caps will not be immune to crashing back down to earth, once the drama is over.
The partnership with the New York-based artificial intelligence company will focus on high-throughput computational antibody design to derive novel leads from ImmunoPrecise’s platforms and accelerate Coronavirus therapeutic antibody discovery and development.
NEW YORK and VICTORIA, March 2, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA” (TSX VENTURE: IPA) (OTC QB: IPATF), through its subsidiary, Talem Therapeutics (talemtherapeutics.com), and the New York-based company EVQLV, Inc. (evqlv.com), announces a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus. IPA’s announcement discloses they have teamed up with EVQLV, an artificial intelligence (AI) company focused on accelerating the discovery and optimization of antibody therapies, as the companies work together to augment and accelerate Talem’s Coronavirus discovery program.
As part of the collaboration, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV plans to utilize its high-speed, evolutionary algorithms with IPA’s expedited B cell Select™ and custom DeepDisplay™ antibody outputs to intelligently discover context-dependent representations that comprise the mutational space of therapeutic candidates for the treatment of SARS-CoV-2 Coronavirus.
“We have been working diligently with EVQLV’s executive team on strategic and operational alignments for the past nine months, an astonishingly fateful advantage under these circumstances, and are able, consequently, to leverage the benefits of this collaboration immediately,” said Dr. Jennifer Bath, President and CEO of IPA. “Our time spent with EVQLV’s management has demonstrated their immense capacity for creativity and thinking outside the box, while absorbing the complexities of IPA’s technologies and outputs. We believe the two teams will create significant therapeutic value together.”
EVQLV will build on IPA’s vast sequence outputs as well as published data to identify and screen hundreds of millions of potential treatments in only days, a feat that would be impossible in a laboratory. Using a wide range of machine learning algorithms, EVQLV can filter candidates with a higher probability of success by computationally measuring and leveraging biological rules and unseen patterns. IPA will narrow the most promising, yet diverse, candidates and demonstrate their unique attributes by synthesizing and wet lab testing specific subsets of selected leads.
“We aim to dramatically reduce the time it takes to identify robust lead candidates with clinical relevance,” added Dr. Bath. “It was clear to us that EVQLV and ImmunoPrecise were a textbook fit. Harnessing the most innovative technologies to more quickly and effectively tackle this global health crisis reflects the core of both company’s philosophies, pushing the frontlines of innovation to improve human health and patient outcomes.”
EVQLV’s algorithms work by initially exploring approximately 10150 therapeutic possibilities against each Coronavirus target the team pursues. Based on the learning the AI gains from this process, EVQLV’s computational engine is able to generate millions of potentially relevant therapeutic antibodies against the SARS-CoV-2 Coronavirus. Using high-performance cloud computing, EVQLV runs a massively parallel process to screen these candidates down to the optimal leads by considering critical antibody characteristics.
In addition to collaborating to produce novel, computationally generated therapies for SARS-CoV-2, EVQLV’s cutting edge AI can be applied to candidates generated from IPA’s rapid discovery programs to quickly expand libraries of therapeutics for other disease indications. Further to the Coronavirus collaboration, the companies plan to continue to work together to leverage EVQLV’s continuously improving AI, along with IPA’s expertise in the design and discovery of biologics, to develop a wide range of novel therapies for patients in need.
“We are excited to be working with the incredible team at IPA” stated EVQLV’s CEO, Andrew Satz. “ImmunoPrecise’s end-to-end antibody discovery capabilities and their highly sophisticated platforms are ideally optimized to leverage our computational technology to rapidly discover treatments for the Coronavirus. By working together, we are supporting our shared commitment of using cutting edge technology to accelerate the identification and validation of novel therapies for those in need.”
Therapeutic candidates developed through this collaboration will remain the ownership of IPA, with commercial royalties issued to EVQLV upon completion of pre-defined, commercial milestones.
About EVQLV
EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to deliver an innovative paradigm that accelerates the speed at which biologic therapies reach patients. Comprised of experts in machine learning, molecular biology, computational biology, pharmacology, software engineering, antibody design, cloud computing, and preclinical/clinical development, EVQLV is on a mission to transform how healing reaches those in need. For further information, visit www.evqlv.com or contact Daniel Gigante at dgigante@evqlv.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com.
About Talem Therapeutics LLC
Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/specialty diseases.
With direct access to world-class, expedited and end-to-end technologies in the antibody discovery and development process, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships. For further information, visit www.talemtherapeutics.com or contact bd@talemtherapeutics.com.
There is no assurance that ImmunoPrecise will be successful in the development of a vaccine and/or therapeutic against the new coronavirus. In particular, the development of a vaccine and/or therapeutic requires significant capital, which will require additional financing by ImmunoPrecise, successful clinical trials and extensive regulatory approvals.
by @newswire on 6 Mar 2020, 17:45
ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures
VICTORIA, March 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it wishes to settle up to $796,875 of previously issued debentures including interest by issuing up to 1,328,125 Shares at a price of $0.60 per Share (the “Debt Settlement”). The purpose of the Debt Settlement is to reduce the ongoing debt obligations of the debentures and is subject to the approval of the TSX Venture Exchange.
Est-ce que quelqu’un saurait pourquoi le CASH item est pas pareil dans le balance sheet et le cashflow statement ?
la différence est le 66 k$ de restricted cash inclus dans les actifs long terme, bien que je suis pas certain que cela devrait apparaître dans le cash flow.
Néanmoins , je trouve les résultats du dernier trimestre excellents , particulièrement si on fait abstraction de l’amortissement du goodwill et intangibles c’est solidement dans le vert et la croissance des ventes au dernier trimestre impressionnante.
Je souhaite qu’ils obtiennent une subvention pour leurs travaux sur le vaccin…
Merci !! 
DSI Alumni Use Machine Learning to Discover Coronavirus Treatments
…
« EVQLV collaborates with Immunoprecise Antibodies (IPA), a company focused on the discovery of therapeutic antibodies. The collaboration will accelerate the effort to develop therapeutic candidates against COVID-19. EVQLV will identify and screen hundreds of millions of potential antibody treatments in only a few days—far beyond the capacity of any laboratory. IPA will produce and test the most promising antibody candidates. »
…
